I am a long on NWBO, and as much as I would like to see the PIII trial succeed, I am not at all clear how the reclassification would change anything for the trial. By this I mean, If the trial originally include group A and group B as the intended treatment group, and if say the trial failed (or was not dispositive in result), when considering both groups as originally intended, then I seriously question that by incorporating a new generally accepted DEFINITION of GBM that now excludes group A from the definition (but not the trial) and that now the trial succeeds when ONLY considering group B and EXCLUDING the originally intended group A, that this would now constitute a successful trial that warrants FDA approval.
Frankly I can see both sides of the argument, and do not see this as a slam dunk for the trial based on this reclassification. I hope I am wrong, but I see this as debatable and can see the FDA going either way.
Market Data 
Markets 
AI
